Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
ShuYu Civilian Pharmacy Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 2/6
ShuYu Civilian Pharmacy has a total shareholder equity of CN¥2.4B and total debt of CN¥3.2B, which brings its debt-to-equity ratio to 136.3%. Its total assets and total liabilities are CN¥9.1B and CN¥6.8B respectively. ShuYu Civilian Pharmacy's EBIT is CN¥155.0M making its interest coverage ratio 1.3. It has cash and short-term investments of CN¥1.3B.
Anahtar bilgiler
136.3%
Borç/özkaynak oranı
CN¥3.23b
Borç
| Faiz karşılama oranı | 1.3x |
| Nakit | CN¥1.30b |
| Eşitlik | CN¥2.37b |
| Toplam yükümlülükler | CN¥6.77b |
| Toplam varlıklar | CN¥9.14b |
Son finansal sağlık güncellemeleri
ShuYu Civilian Pharmacy (SZSE:301017) Use Of Debt Could Be Considered Risky
Jun 20
These 4 Measures Indicate That ShuYu Civilian Pharmacy (SZSE:301017) Is Using Debt Extensively
Mar 04Recent updates
A Piece Of The Puzzle Missing From ShuYu Civilian Pharmacy Corp., Ltd.'s (SZSE:301017) 25% Share Price Climb
Sep 06ShuYu Civilian Pharmacy (SZSE:301017) Could Be Struggling To Allocate Capital
Jul 25ShuYu Civilian Pharmacy Corp., Ltd. (SZSE:301017) Shares May Have Slumped 32% But Getting In Cheap Is Still Unlikely
Jun 21ShuYu Civilian Pharmacy (SZSE:301017) Use Of Debt Could Be Considered Risky
Jun 20These 4 Measures Indicate That ShuYu Civilian Pharmacy (SZSE:301017) Is Using Debt Extensively
Mar 04Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: 301017's short term assets (CN¥5.2B) exceed its short term liabilities (CN¥4.9B).
Uzun Vadeli Yükümlülükler: 301017's short term assets (CN¥5.2B) exceed its long term liabilities (CN¥1.9B).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: 301017 'nin net borç/özsermaye oranı ( 85.1% ) yüksek olarak kabul edilir.
Borcun Azaltılması: 301017's debt to equity ratio has increased from 4.7% to 136.3% over the past 5 years.
Borç Kapsamı: 301017's debt is not well covered by operating cash flow (4%).
Faiz Kapsamı: 301017's interest payments on its debt are not well covered by EBIT (1.3x coverage).